The Relationship of Visfatin Levels to Inflammatory Cytokines and Left Ventricular Hypertrophy in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients

Figures & data

Table 1 Comparison of selected characteristics between CAPD and hemodialysis patients and healthy subjects

	CAPD patients (n = 30)	Hemodialysis patients (n = 31)	Control subjects(n = 21)
Gender (F/M)	16/14	15/16	10/11
Age (year)	46.6 ± 12.7	49.6 ± 8.5	49.6 ± 8.5
Duration of dialysis (months)	75.3 ± 52.8	53.4 ± 36.5	—
Hypertension prevalence (%)	70	67.7	—
Kt/V	1.58 ± 0.49	1.37 ± 0.25	—
BMI (kg/m^2)	24.4 ± 4.2	22.6 ± 3.9	26.3 ± 3.7
Systolic BP (mmHg)	122.6 ± 9.2	120.7 ± 8.2	121.7 ± 8.7
Diastolic BP (mmHg)	72.4 ± 10.7	70.8 ± 8.9	70.4 ± 6.4
Fasting blood glucose (mg/dL)	97.97 ± 25.76	90.32 ± 30.72	90.82 ± 8.47
Hemoglobin (g/dL)^†	11.357 ± 1.55	11.02 ± 1.88	14.63 ± 1.21
Albumin (g/dL)^‡	4.07 ± .53	4.42 ± .34	4.97 ± .31
Calcium (mg/dL)^§	9.14 ± .68	8.78 ± .64	9.61 ± .44
Phosphate (mg/dL)^║	4.75 ± 1.12	5.42 ± 1.39	3.42 ± .39
T-cholesterol (mg/dL)	191.29 ± 42.99	163.00 ± 45.29	191.41 ± 23.33
LDL-cholesterol (mg/dL)^#	109.32 ± 33.02	90.54 ± 34.14	120.12 ± 21.26
Triglycerides (mg/dL)**	170.39 ± 83.71	136.68 ± 61.82	112.12 ± 34.18
hsCRP (mg/dL)	1.32 ± 2.79	0.48 ± 0.60	0.98 ± 2.21
IL-6 (pg/mL)^††	12.91 ± 14.63	10.37 ± 11.85	4.51 ± 7.52
TNF-α (pg/mL)^‡‡	36.03 ± 9.68	32.43 ± 8.57	9.25 ± 8.81
Visfatin (ng/mL)^§§	265.27 ± 387.86	97.68 ± 244.96	41.33 ± 48.87

*Hemodialysis vs. control, p = 0.009.

^†CAPD vs. control, p = .000; hemodialysis vs. control, p = .002.

^‡CAPD vs. hemodialysis, p = .01; CAPD vs. control, p = .000; hemodialysis vs. control, p = .002.

^§CAPD vs. control, p = .04; hemodialysis vs. control, p = .002.

^║Hemodialysis vs. control, p = .002; CAPD vs. control, p = .001.

^#Hemodialysis vs. control, p = .016.

**CAPD vs. control, p = .018.

^††CAPD vs. control, p = 0.03.

^‡‡CAPD vs. control, p = 0.001; hemodialysis vs. control, p = 0.001.

^§§CAPD vs. hemodialysis, p = 0.04; CAPD vs. control, p = 0.01.

Abbreviation: hsCRP = high sensitive C-reactive protein.

Figure 1. Comparison of visfatin serum levels between CAPD and hemodialysis patients and healthy subjects.

Figure 2. Comparison of IL-6 serum levels between CAPD and hemodialysis patients and healthy subjects.

Figure 3. Comparison of TNF-α serum levels between CAPD and hemodialysis patients and healthy subjects.

Table 2 Comparison of echocardiographic parameters between CAPD and hemodialysis patients and healthy subjects

Echocardiographic parameters	CAPD patients (n = 30)	Hemodialysis patients (n = 31)	Control subjects (n = 21)
Ejection fraction (%)	61.52 ± 13.03	66.40 ± 6.91	67.04 ± 4.72
Fractional shortening (%)	36.93 ± 5.29	33.42 ± 7.85	37.24 ± 3.53
Em (cm/sn)	8.48 ± 2.14	9.61 ± 2.80	10.53 ± 2.21
Em/Am (cm/sn)^†	.89 ± .35	1.11 ± .45	1.16 ± .36
IVRT (msn)^‡	94.78 ± 25.09	97.62 ± 18.32	76.71 ± 15.29
LVMI (gr/m^2,7)^§	59.84 ± 16.40	51.39 ± 15.22	44.06 ± 11.05
LVH prevalence (%)	70	67.7	—

*CAPD vs. control, p = 0.01.

^†CAPD vs. control, p = 0.03.

^‡CAPD vs. control, p = 0.01; hemodialysis vs. control, p = 0.008.

^§CAPD vs. control, p = 0.002.

Abbreviations: Em = early mitral mitral annular velocities, Am = late mitral mitral annular velocities, IVRT = isovolumetric relaxation time, LVMI = left ventricular mass index, LVH = left ventricular hypertrophy.